Log in

FAIR data policies can benefit biotech startups

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Alharbi, E., Skeva, R., Juty, N., Jay, C. & Goble, C. Data Intell. 3, 507–527 (2021).

  2. Harrow, I., Balakrishnan, R., McGinty, H. K., Plasterer, T. & Romacker, M. Drug Discov. Today 27, 1441–1447 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. van Vlijmen, H. et al. Data Intell. 2, 276–284 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

We thank A. X. Yee for writing and editing assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kate Hardy.

Ethics declarations

Competing interests

K.H. is Senior Director, Informatics and Technology, at MOMA Therapeutics. S.H. is Head of Genedata Screener Business Unit, at Genedata, AG.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hardy, K., Heyse, S. FAIR data policies can benefit biotech startups. Nat Biotechnol 41, 1060–1061 (2023). https://doi.org/10.1038/s41587-023-01892-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01892-8

  • Springer Nature America, Inc.

Navigation